Episode May 23, 2019

Young Blood Transfers For Anti-Aging, Alzheimers, Parkinson's & More: The Future Of One Of The Most Cutting-Edge Medical Protocols That Exists.

You've no doubt heard of controversial "young blood transfers", made popular of late in the anti-aging and longevity industry by articles such as:

-Questionable “Young Blood” Transfusions Offered in U.S. as Anti-Aging Remedy

-New Yorkers will soon be able to have the blood of 16- to 25-year-olds transfused into their body. But does it actually do anything?

-Startups Flock to Turn Young Blood Into an Elixir of Youth

But what has completely flown under the radar is the fact that plasma transfusions of young blood have been found in clinical research studies to have never-before-seen effects on chronic health conditions such as Alzheimer's, Parkinson's, autoimmunity and many others.

In today's podcast, with Mark Urdahl and his lead nurse Gloria, you'll get never-before-heard breakthrough information on how young blood transfusions really work for these conditions, along with their true effects on anti-aging and longevity. Mark Urdahl, one of my guests on this podcast, serves as Chairman and CEO of the Young Blood Institute, a non-profit corporation conducting clinical trials in the use of therapeutic plasma exchange as a modality to systemically prevent cellular senescence and the onset of associated immunological, neurological, and cardiovascular disorders.

Mr. Urdahl and his team at the Young Blood Institute have also pioneered the concurrent use of the world’s most advanced, state-of-the-art, ultrasensitive, high-precision blood serum measurement technologies to capture comprehensive “big data” of the human body, an unprecedented combination of testing technologies in human medicine or human clinical research, in order to understand never-before-seen correlations which might lead to discovery of root causes of age-associated disorders.

He began his career with IBM Biomedical Systems, which, in partnership with the National Cancer Institute, invented the world’s first automated blood cell separator, first commercially produced by IBM in the 70’s as the IBM 2997. After IBM sold its Biomedical Systems business unit to COBE Laboratories in 1984, Mr. Urdahl became a systems engineer supporting IBM large systems accounts, including notable innovators in health care management.

Mr. Urdahl went on to lead a distinguished career at IBM, where he held management positions in marketing and sales, technology development, corporate development. After IBM, he founded Applied Science Fiction (ASF), a digital imaging company where he served as Chairman and CEO, overseeing the development of over 150 patent applications and licensing its technology to nearly every major imaging OEM worldwide, including Nikon, Agfa, Minolta, and many others.

Mr. Urdahl subsequently formed the Young Blood Institute as a non-profit 501 (c) (3) corporation to research anti-aging therapies under clinical trials, recruiting world-class principal investigators, establishing a nation-wide network of nurses and private care physicians, creating the most advanced biomarker testing platform in the world, and developing a “big data” database capable of storing data in the cloud in perpetuity.

In 2008 Mr. Urdahl led an investment group to acquire the storage network monitoring business unit of Finisar Corp, including a portfolio of 20+ patents/applications, to form a privately held company, Virtual Instruments. He subsequently formed the Young Blood Institute to research anti-aging therapies under clinical trials, recruiting world-class principal investigators, establishing a nation-wide network of nurses and private care physicians, creating the most advanced biomarker testing platform in the world, and developing a “big data” database capable of storing data in the cloud in perpetuity.

During our discussion, you'll discover: -The history of the world's first blood cell separator...